|
Post by dreamboatcruise on Oct 1, 2014 11:20:31 GMT -5
... Are they naked shorting to do this? ... JPG They shall not get away with that. I did some buying today au naturale. That'll show those naked shorters.
|
|
|
Post by mnkdorbust on Oct 1, 2014 17:56:19 GMT -5
... Are they naked shorting to do this? ... JPG They shall not get away with that. I did some buying today au naturale. That'll show those naked shorters. As did i today and yesterday. Not significant purchases but au naturale as well. Getting low on dry powder...
|
|
|
Post by mnholdem on Oct 1, 2014 18:14:22 GMT -5
"I did some buying today au naturale" - is that like the commercial where you can book a trip online in your underwear?
|
|
|
Post by jpg on Oct 1, 2014 19:13:18 GMT -5
Interesting observation maybe?
I have Google alerts set up on Mannkind it seems as if the majority of them I get from this Proboard are negative comments like this:
Mannkind As-it-happens update ⋅ October 2, 2014 WEB What Happens if PPS Drops Below $5? MannKind MNKD Message Board Ok - so there has been speculation that short covering could commence at $5.50/share - as in, right now. There's also a fair amount of thought that ...
It is as if they were being somehow selected out and given to Google?
Paranoia on my part?
JPG
|
|
|
Post by dreamboatcruise on Oct 1, 2014 19:19:48 GMT -5
As the old saying goes, sorta... Just because you're paranoid, doesn't mean they aren't out to get Mannkind.
|
|
|
Post by jpg on Oct 2, 2014 5:47:08 GMT -5
This once every 6 months mini pump with a GLP1 (exenatide) will be interesting to follow. This is obviously partial data and there seems to be some strangely worded statements about the stage of development of the minipump/ product. Ithey are only presenting their data in June 2015? That is kind of far away? And they will be doing 2 more phase 2s with a different pump if I understand their press release? Again surprising. Kind of like a company we know... It certainly would give all GLP1s a big run for their money. I would guess that to minimize surgical removal of the pump (for side effects) patients would be tried on a long acting GLP1 drug first then switched to these pumps? I wonder if the concerns about GLP1s would be more or less with this type of technology? The company says they could be on the market in 2016. Somehow from what I read about what they are doing I somehow doubt that very seriously. 2017 or 2018 maybe if all goes well? One thing I do know is there will be no lack of shorts using this to hurt us when the markets open... Can't we ever get a break? www.marketwatch.com/story/intarcia-announces-two-positive-phase-3-trials-for-itca-650-in-type-2-diabetes-freedom-1-and-freedom-1-high-baseline-hbl-study-results-2014-10-01intarcia.com/media/press-releases/2014-oct-1-phase-3.htmlJPG
|
|
|
Post by brentie on Oct 2, 2014 9:34:39 GMT -5
|
|
|
Post by daduke38 on Oct 2, 2014 9:57:37 GMT -5
Pretty sobering. Honestly, the writer is hard to follow, but some thing in there that are concerning, with logic. I'm not the brightest bulb on this board, so I would be intrested in any rebuttals! TIA
|
|
|
Post by dreamboatcruise on Oct 2, 2014 10:55:54 GMT -5
Pretty sobering. Honestly, the writer is hard to follow, but some thing in there that are concerning, with logic. I'm not the brightest bulb on this board, so I would be intrested in any rebuttals! TIA He doesn't understand the technology. He doesn't even know how a lien works... or is purposefully misrepresenting things. I wouldn't pay any attention to it. Every investor should read the filings which he is citing, but don't bother thinking this guy provides any insight into the filings. All companies list risks. If the exists of those is upsetting then any stock is going to be outside your risk profile. I'd guess close to 100% of companies that manufacture something have a risk statement about 3rd party patents. I bought some more after reading it. I'm now at about 95% of what I intend to hold. I had 50/50 shares and calls going into partnership. The calls have since expired worthless and as the stock is going done I'm replacing the lost calls with actual shares.
|
|
|
Post by daduke38 on Oct 2, 2014 11:08:38 GMT -5
Pretty sobering. Honestly, the writer is hard to follow, but some thing in there that are concerning, with logic. I'm not the brightest bulb on this board, so I would be intrested in any rebuttals! TIA He doesn't understand the technology. He doesn't even know how a lien works... or is purposefully misrepresenting things. I wouldn't pay any attention to it. Every investor should read the filings which he is citing, but don't bother thinking this guy provides any insight into the filings. All companies list risks. If the exists of those is upsetting then any stock is going to be outside your risk profile. I'd guess close to 100% of companies that manufacture something have a risk statement about 3rd party patents. I bought some more after reading it. I'm now at about 95% of what I intend to hold. I had 50/50 shares and calls going into partnership. The calls have since expired worthless and as the stock is going done I'm replacing the lost calls with actual shares. I re-read it and you are right. I also just bought some more. Honestly it took 2 reads to see what the heck he is talking about. And anything that is written that way is junk.
|
|
|
Post by mnholdem on Oct 2, 2014 15:26:30 GMT -5
Remember Al's comment about pumps/AP in his last interview? Too expensive & too complex. I agree and am not worried. More bashing pundit fodder that will be printed then forgotten.
|
|
|
Post by brentie on Oct 2, 2014 17:21:23 GMT -5
|
|
|
Post by brentie on Oct 2, 2014 19:00:58 GMT -5
|
|
|
Post by brentie on Oct 2, 2014 22:20:11 GMT -5
There's some interesting stuff in here. I would start watching around the 45 minute mark. He talks about some of the different uses for Technosphere.
|
|
|
Post by seanismorris on Oct 2, 2014 23:42:34 GMT -5
In the presentation OXM is mentioned as one of the trials performed using Techosphere. It does look like something worth pursuing.
Heres some information
(D-Ser2)Oxm[mPEG-PAL]: a novel chemically modified analogue of oxyntomodulin with antihyperglycaemic, insulinotropic and anorexigenic actions. Barry D Kerr, Peter R Flatt, Victor A Gault PMID 20735990 → see in PubMed | read abstract here Oxyntomodulin (Oxm) is a hormone which has been shown to exhibit a range of potentially beneficial actions for alleviation of obesity-diabetes. However, exploitation of Oxm-based therapies has been severely restricted due to degradation by the enzyme dipeptidylpeptidase-IV (DPP-IV). Thus, the aim of this study was to assess the glucose-lowering, insulin-releasing and anorexigenic actions of chemically modified, enzyme-resistant analogues of Oxm. Oxm, (d-Ser(2))Oxm and (d-Ser(2))Oxm[mPEG-PAL], were incubated with DPP-IV to assess enzyme stability and pancreatic beta-cells to evaluate insulin secretion. cAMP production was assessed using glucagon-like peptide-1 (Glp-1) and glucagon receptor transfected cells. In vivo effects of Oxm analogues on glucose homeostasis, insulin secretion, food intake and bodyweight were examined in obese diabetic (ob/ob) mice. (d-Ser(2))Oxm[mPEG-PAL] displayed enhanced DPP-IV resistance compared to (d-Ser(2))Oxm and Oxm. All peptides demonstrated similar in vitro cAMP and insulin-releasing actions, which was associated with dual action at Glp-1 and glucagon receptors. Acute administration of (d-Ser(2))Oxm[mPEG-PAL] and (d-Ser(2))Oxm reduced plasma glucose and food intake, whilst plasma insulin levels were elevated. Once-daily administration of (d-Ser(2))Oxm[mPEG-PAL] for 14 days to ob/ob mice decreased food intake, bodyweight, plasma glucose and increased plasma insulin. Furthermore, daily (d-Ser(2))Oxm[mPEG-PAL] improved glucose tolerance, increased glucose-mediated insulin secretion, pancreatic insulin content, adiponectin and decreased both visfatin and triglyceride levels. The ability of enzyme-resistant (d-Ser(2))Oxm[mPEG-PAL] to improve glucose homeostasis, insulin secretion, satiety, bodyweight and markers of fat metabolism suggests significant promise for Oxm-based therapies for obesity-diabetes.
|
|